Company Overview of Daiichi Sankyo, Inc.
Daiichi Sankyo, Inc. operates as a research-based pharmaceutical company that discovers, develops, and commercializes pharmaceutical products. It offers olmesartan medoxomil, hydrochlorothiazide, prasugrel, cevimeline HCI, amlodipine, colesevelam HCI, and vemurafenib tablets. The company provides therapies in hypertension, dyslipidemia, diabetes, acute coronary syndrome, and metastatic melanoma areas. It serves patients, and professional organizations and institutions in the United States and internationally. Daiichi Sankyo, Inc. was formerly known as Sankyo Pharma Inc. and changed its name to Daiichi Sankyo, Inc. in April 2006. The company was founded in 1996 and is based in Parsippany, New...
Two Hilton Court
Parsippany, NJ 07054
Founded in 1996
Key Executives for Daiichi Sankyo, Inc.
Chairman, President, President of Daiichi Sankyo Pharma Development, Global Head of Research & Development - Daiichi Sankyo Ltd and Senior Executive Officer - Daiichi Sankyo Ltd
Vice President of Operations
Chief Executive Officer of Daiichi Sankyo Co., Ltd. and President of Daiichi Sankyo Co., Ltd.
President of Commercial Operations
Executive Vice President and Head of Global Business Development
Compensation as of Fiscal Year 2014.
Daiichi Sankyo, Inc. Key Developments
Daiichi Sankyo, Inc. Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 08:55 AM
Feb 22 15
Daiichi Sankyo, Inc. Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 08:55 AM. Venue: The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St, 40th Floor (D Elevator Bank), New York, NY10007, United States. Speakers: Francis Kern, Senior Director of External Scientific Affairs.
Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Initiate Two Phase 3 Clinical Trials on Charleston's Lead Product, CL-108
Nov 20 14
Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. initiated two Phase 3 clinical trials on CL-108, Charleston Laboratories' lead product in development. CL-108 is a novel, bi-layered tablet containing 7.5 mg of hydrocodone and 325mg of acetaminophen with 12.5mg of immediate-release promethazine. The studies will evaluate the safety and efficacy of CL-108, the intended to treat moderate to severe acute pain while reducing nausea and vomiting, common side effects of opioids. One study is a randomized, double-blind, placebo- and active-controlled trial conducted in patients following bunionectomy surgery at 3 major research centers in the United States. The second study is being conducted at 17 research centers across the country in patients suffering moderate to severe acute pain from osteoarthritis of the knee or hip. The results of the first Phase 3 trial were published in abstract form ("Demonstration of the safety and efficacy of CL-108 for moderate-to-severe pain with reduction of opioid-induced nausea and vomiting") in the April 2014 issue of the Journal of Pain, the official journal of the American Pain Society. The study was terminated early by an external Data Safety Monitoring Board because of the significant (p < 0.01) evidence of the safety and efficacy of CL-108.
Daiichi Sankyo, Inc. Appoints Ken Keller as President of Commercial Operations Effective May 1, 2014
Apr 18 14
Daiichi Sankyo, Inc. announced that Ken Keller will join the company as President of its Commercial operations in the United States starting May 1, 2014. In his role, Mr. Keller will be responsible for leading marketing, sales, medical affairs and supply chain operations for Daiichi Sankyo in the U.S. Ken brings with him more than 25 years of pharmaceutical experience, with career highlights including building a $3 billion business unit as well as leading commercialization for four of the world's top selling biologic medicines. His broad experience and proven success will be a tremendous asset to Daiichi Sankyo. Most recently, Mr. Keller was Executive Vice President and Chief Operating Officer at Spectrum Pharmaceuticals, where he was responsible for global commercial, medical, research and development, and manufacturing. Also responsible for business development at Spectrum, he was integral to the successful acquisition and integration of Talon Therapeutics into the company. Prior to Spectrum, Mr. Keller spent 21 years at Amgen rising through the organization as a respected leader in sales and marketing, general management and joint ventures. He brings with him deep experience in several therapeutic areas aligned with Daiichi Sankyo's focus, including oncology and primary care medicines. His most recent appointments at Amgen were as Vice President and General Manager for two of the company's highly successful business units (bone health and inflammation), as well as Managing Director at Amgen Limited in the United Kingdom and Ireland. With the appointment of Mr. Keller as the head of commercial operations at Daiichi Sankyo, Inc., Dr. Glenn Gormley will assume the role of Executive Chairman and President, Daiichi Sankyo, Inc., and will retain his roles as President, Daiichi Sankyo Pharma Development and as the Global Head of R&D for Daiichi Sankyo Co. Ltd. Greg Barrett, who served as interim president for Commercial operations for the past seven months, will remain Vice President of Marketing and Managed Markets at Daiichi Sankyo, Inc.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|